# US 2017/0253931 A1 · Post-treatment breast cancer prognosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253931 A1
- Document ID: US20170253931A1
- Status: Published application
- Kind: A1
- Application number: 15/298,128
- Filed: 2016-10-19
- Published: 2017-09-07
- Earliest claimed: 2010-12-09
- Assignees: Biotheranostics, Inc.; The General Hospital Corporation
- Applicants: Biotheranostics, Inc.; The General Hospital Corporation
- Inventors: Dennis SGROI; Mark G. ERLANDER; Yi ZHANG; Catherine A. SCHNABEL
- Web page: https://patentgrep.com/patent/US20170253931A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and/or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and/or cancer metastasis.

## Claims

### Claim 1

A method of treating breast cancer in a subject who has undergone removal of ER+ breast cancer and has been treated with a first endocrine therapy of a selective estrogen receptor modulator (SERM), a selective estrogen receptor down-regulator (SERD), or an aromatase inhibitor (AI), the method comprising:
preparing cDNA from nucleic acids in a sample of ER+ breast cancer cells from the subject,
measuring the expression level of one or more genes comprising the HoxB13 gene from said cDNA,
comparing the expression level with reference expression levels for the same one or more genes from ER+ breast cancer cells from reference patients,
classifying the subject as expected to benefit from a change in treatment or not expected to benefit from a change in treatment, wherein the subject is classified as expected to benefit from a change in treatment when the subject's compared expression level is (a) above the compared expression levels from reference patients that did not have cancer recurrence and/or (b) not below the compared expression levels from reference patients that did have cancer recurrence, and
either (i) treating the subject with a different second endocrine therapy after cessation of treatment with the first endocrine therapy based on classifying the subject as expected to benefit from a change in treatment, or (ii) treating the subject with the first endocrine therapy based on classifying the subject as not expected to benefit from a change in treatment.

### Claim 2 (depends on 1)

The method according to claim 1, wherein
(a) said one or more genes further comprise the IL17BR gene, and
(b) said comparing the expression level with reference expression levels comprises comparing a ratio of expression levels of HoxB13:IL17BR (“H:I ratio”) for the subject to H:I ratios for the reference patients, and
(c) the subject's compared expression level is the subject's H:I ratio, and the compared expression levels from reference patients are the H:I ratios for the reference patients.

### Claim 3 (depends on 1)

The method of claim 1, wherein said nucleic acids are mRNA from said sample, and said measuring comprises nucleic acid amplification.

### Claim 4 (depends on 1)

The method of claim 1, wherein said measuring comprises using an array.

### Claim 5 (depends on 1)

The method of claim 1, wherein said sample is dissected from tissue removed from said subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first endocrine therapy is for about five years.

### Claim 7 (depends on 1)

The method of claim 1, wherein said sample is a formalin fixed paraffin embedded (FFPE) sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein (i) the first endocrine therapy is tamoxifen treatment, (ii) the method further comprises treating said subject with the second endocrine therapy after cessation of tamoxifen treatment, and (iii) the second endocrine therapy comprises treatment with letrozole.

### Claim 9 (depends on 1)

The method of claim 1 wherein said cancer is ductal carcinoma in situ (DCIS) and said cancer recurrence comprises local recurrence.

### Claim 10 (depends on 1)

The method of claim 1, wherein said treating comprises treating the subject with a different second endocrine therapy after cessation of treatment with the first endocrine therapy based on classifying the subject as expected to benefit from a change in treatment.

### Claim 11 (depends on 10)

The method of claim 10 wherein the first endocrine therapy is treatment with tamoxifen and the second endocrine therapy is treatment with letrozole.

### Claim 12 (depends on 1)

The method of claim 1, wherein the second endocrine therapy is a SERM, a SERD or an AI.

### Claim 13 (depends on 12)

The method of claim 12, wherein (i) the first endocrine therapy is of a first type selected from the group consisting of a SERM, a SERD, and an AI, (ii) the second endocrine therapy is of a second type selected from the group consisting of a SERM, a SERD, and an AI, and (iii) the first type and second type are different.

### Claim 14

A method of treating breast cancer in a subject who has undergone removal of ER+ breast cancer and has been treated with a first endocrine therapy of a selective estrogen receptor modulator (SERM), a selective estrogen receptor down-regulator (SERD), or an aromatase inhibitor (AI), the method comprising:
preparing cDNA from nucleic acids in a sample of ER+ breast cancer cells from the subject,
measuring the expression level of the HoxB13, IL17BR, Bub1B, CENPA, NEK2, RACGAP1, and RRM2 genes from said cDNA,
calculating a ratio of expression levels of HoxB13:IL17BR (“H:I ratio”), and a summation value of expression levels of Bub1B, CENPA, NEK2, RACGAP1, and RRM2 using the subject's expression levels,
combining the H:I ratio with the summation value to obtain a subject index value,
comparing the subject index value to a reference index value for ER+ breast cancer patients that did not have cancer recurrence and/or ER+ breast cancer patients that did have cancer recurrence,
classifying the subject as having a high risk of recurrence of breast cancer if the subject's index value is (a) above the reference index value for the patients that did not have cancer recurrence and/or (b) not below the reference index value for the patients that did have cancer recurrence, and
treating the subject classified as having a high risk of recurrence with a second endocrine therapy.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject index value is a Breast Cancer Index (BCI) value, wherein the BCI is a continuous risk model built by combining an H:I ratio and a summation value of expression levels of Bub1B, CENPA, NEK2, RACGAP1, and RRM2 from a plurality of reference patients.

### Claim 16 (depends on 15)

The method of claim 15, wherein the BCI is further categorized into high risk, intermediate risk and low risk index values.

### Claim 17 (depends on 14)

The method of claim 14, wherein the second endocrine therapy comprises treating the subject with a SERM, a SERD or an AI after cessation of the first endocrine therapy.

### Claim 18 (depends on 14)

The method of claim 14, wherein the second endocrine therapy is different from the first endocrine therapy.

### Claim 19 (depends on 18)

The method of claim 18, wherein (i) the first endocrine therapy is of a first type selected from the group consisting of a SERM, a SERD, or an AI, (ii) the second endocrine therapy is of a second type selected from the group consisting of a SERM, a SERD, or an AI, and (iii) the first type and second type are different.

### Claim 20

A method of treating breast cancer in a subject who has undergone removal of ER+ breast cancer and has been treated with a first endocrine therapy of a selective estrogen receptor modulator (SERM), a selective estrogen receptor down-regulator (SERD), or an aromatase inhibitor (AI), the method comprising:
preparing cDNA from nucleic acids in a sample of ER+ breast cancer cells from the subject,
measuring the expression level of the HoxB13 gene from said cDNA,
comparing the expression level with reference expression levels for the same gene from ER+ breast cancer cells from reference patients,
classifying the subject as having a high risk of recurrence of breast cancer if the subject's expression level is (a) above the expression levels from reference patients that did not have cancer recurrence or (b) not below the expression levels from reference patients that did have cancer recurrence, and
treating the subject classified as having a high risk of recurrence with a second endocrine therapy.
